eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Dec 27, 2024, 4:00 PM EST
eFFECTOR Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | - | 3.55 | 1.43 | 42 | - |
| Revenue Growth (YoY) | - | - | 148.46% | -96.60% | - | - |
| Cost of Revenue | 21.62 | 22.92 | 23.31 | 19.96 | 21.83 | 23.89 |
| Gross Profit | -21.62 | -22.92 | -19.76 | -18.53 | 20.17 | -23.89 |
| Selling, General & Admin | 11.09 | 10.93 | 12.64 | 13.37 | 4.35 | 4.72 |
| Operating Expenses | 11.09 | 10.93 | 12.64 | 13.37 | 4.35 | 4.72 |
| Operating Income | -32.7 | -33.84 | -32.4 | -31.9 | 15.82 | -28.61 |
| Interest Expense | -2.98 | -2.92 | -2.25 | -1.76 | -1.33 | -1.38 |
| Interest & Investment Income | 1.07 | 0.97 | 0.44 | 0.01 | 0.07 | 0.24 |
| Other Non Operating Income (Expenses) | -0.02 | -0.03 | -0.57 | 1.04 | 0.01 | 0.01 |
| EBT Excluding Unusual Items | -34.64 | -35.82 | -34.79 | -32.62 | 14.56 | -29.74 |
| Other Unusual Items | 0.01 | 0.01 | 12.12 | 48.42 | - | 15.53 |
| Pretax Income | -34.63 | -35.81 | -22.67 | 15.8 | 14.56 | -14.21 |
| Income Tax Expense | - | - | - | - | 0.35 | - |
| Earnings From Continuing Operations | -34.63 | -35.81 | -22.67 | 15.8 | 14.21 | -14.21 |
| Minority Interest in Earnings | - | - | - | - | -14.05 | - |
| Net Income | -34.63 | -35.81 | -22.67 | 15.8 | 0.17 | -14.21 |
| Net Income to Common | -34.63 | -35.81 | -22.67 | 15.8 | 0.17 | -14.21 |
| Net Income Growth | - | - | - | 9416.87% | - | - |
| Shares Outstanding (Basic) | 3 | 2 | 2 | 1 | 0 | 0 |
| Shares Outstanding (Diluted) | 3 | 2 | 2 | 1 | 0 | 0 |
| Shares Change (YoY) | 68.04% | 32.77% | 14.37% | 1256.16% | 122.00% | - |
| EPS (Basic) | -12.42 | -16.37 | -13.76 | 26.15 | 2.94 | -297.06 |
| EPS (Diluted) | -12.42 | -16.37 | -13.76 | 11.00 | 2.82 | -297.06 |
| EPS Growth | - | - | - | 290.68% | - | - |
| Free Cash Flow | -29.28 | -29.65 | -26.09 | -24.93 | 13.68 | -27.6 |
| Free Cash Flow Per Share | -10.50 | -13.56 | -15.84 | -17.31 | 128.83 | -577.03 |
| Gross Margin | - | - | - | - | 48.02% | - |
| Operating Margin | - | - | -911.99% | -2230.56% | 37.66% | - |
| Profit Margin | - | - | -637.91% | 1104.76% | 0.40% | - |
| Free Cash Flow Margin | - | - | -734.34% | -1743.36% | 32.57% | - |
| EBITDA | -32.59 | -33.73 | -32.35 | -31.87 | 15.98 | -28.3 |
| EBITDA Margin | - | - | - | - | 38.05% | - |
| D&A For EBITDA | 0.11 | 0.11 | 0.05 | 0.02 | 0.16 | 0.31 |
| EBIT | -32.7 | -33.84 | -32.4 | -31.9 | 15.82 | -28.61 |
| EBIT Margin | - | - | - | - | 37.66% | - |
| Effective Tax Rate | - | - | - | - | 2.41% | - |
| Revenue as Reported | - | - | - | - | 42 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.